ARCHIVES

Talactoferrin Second-Line Therapy Increases Survival In Stage IIIB/IV

This article is from The Cancer Letter archive.

Vol. 34 No. 10 | October 28, 2011

Download PDF Visit The Full Archive

Related Articles

FASEB Says NIH Budge Should Reach $10 Bil. In Fiscal 1993

January 10, 1992

UT System Chancellor to Travel to MD Anderson After Faculty Senate Survey Finds Plunging Morale

September 6, 2013

In Brief: Orvile Kelley, Make Today Count Founder, Dies; Elli Kohen Honored By Pap Institute

July 4, 1980

Troubled Roswell Park Cancer Institute Bets On Recruitment To Regain Its Luster.

January 19, 2001

Randomized Trial Finds Supplement Use Didn’t Prevent Prostate Cancer After 5 Years.

October 31, 2008

An “insurgency” targets randomized trials, demands access to investigational drugs.

August 5, 2005